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Aim: To evaluate the prognostic relevance of key cell cycle regulatory proteins p53, p16INK4a, pRb and Cyclin D1 expression, the 
presence of high risk HPVs and their association with clinicopathological parameters and the clinical follow up in ovarian cancer 
patients. Methods: 53 cases of primary ovarian serous carcinomas were immunohistochemically examined for the expression of p53, 
p16INK4a, pRb and Cyclin D1 proteins. Tumor DNA was extracted from paraffin blocks and subjected to HPV 16 and 18 testing. The 
association between HPV 16 and 18 E6 oncoprotein and cell cycle proteins expression in ovarian carcinomas also was evaluated 
by immunohistochemistry. Results: We demonstrated that a majority of moderately and poorly differentiated ovarian carcinomas are 
characterized by strong expression of p53 and p16INK4a proteins. In contrast, strong staining with cyclin D1 antibody was observed 
in well differentiated tumors. The correlation between strong p53, pRb, Cyclin D1 and clinical stages of disease was also observed. 
We show that patients with high positivity for p53, p16INK4a and Cyclin D1 had a poor prognosis and reduced overall survival. The 
presence of HPV 16/18 DNA was detected in 17% of ovarian carcinomas. The tumor tissues that reacted positively to HPV E6 an-
tibody in focal and diffuse manners had also significantly low p53 expression profile. Conclusion: These findings suggest that p53, 
p16INK4a and Cyclin D1 expression and HPV infection may represent a promising tool toward the identification of ovarian cancer 
patients with poorer prognosis and shorter survival who might therefore need a more aggressive therapy and HPV screening.
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Ovarian cancer (OC) is a lethal and devastating 
gynecologic malignancy in the developing world [1]. 
Factors influencing epithelial ovarian cancer etiology 
have been postulated to be hormonal, genetic and also 
some environmental factors such as infections [2], 
nutrition, and chemical exposure [3]. However, the role 
of environmental factors is not as yet well defined. Mo-
lecular pathogenesis of ovarian carcinomas is known 
to be heterogeneous and possibly involves multiple 
precursor lesions in different pathways and its develop-
ment includes dysregulation of cell proliferation, par-
ticularly the control of G1-S phase [4].
Well known tumor suppressor retinoblastoma gene 
product pRB functions to inhibit entry of cells into the 
S-phase. This is an important checkpoint in the cellular 
lifecycle mediated by hypophosphorylation of pRb 
by cyclin family of enzymes including Cyclin D1 in nor-
mal cells [5]. Disruption of this interaction has been 
positively correlated with malignant transformation 
in the cell [4, 5]. There are several known mechanisms 
of pRb pathway disruption in malignant tumors where 
Cyclin D1 overexpression due to amplification, muta-
tion, chromosome translocation or other mechanisms 
appears to result dysregulation of late G1 restriction 
point and give rise uncontrolled proliferation of cells 
[4]. The p16INK4a gene encodes a protein that regulates 
the G1-S phase cell cycle progression by inhibiting 
cyclin-dependent kinases 4 and 6 (CDK4 and 6) and 
cyclin D1 [6]. The CDK 4, 6 and cyclin D1 are required 
for phosphorylation of pRB. The transition of cell cycle 
from G1 to S phase is triggered by the activation of the 
Cyclin D1/CDK4, 6 complex [6]. Barbieri et al. (2004) 
propose that Cyclin D1 overexpression is an early event 
in malignant transformation of ovarian epithelial cells 
and may have prognostic significance [7]. One mecha-
nism of pRb disruption is loss or mutation of p16INK4a [4, 
6]. This event induces the upregulation of Cyclin D1/
Cdk 4 and CyclinD1/Cdk6 complexes and pRb phos-
phorylation resulting in the subsequent release of E2F 
and transcription of genes of cell proliferation [4–6].
The most frequent documented genetic alteration 
in OC is a mutation of the potent tumor suppressor 
gene TP53 which encodes a multifunctional protein 
[8]. p53 regulates the cell cycle at the G1 checkpoint 
and is primarily stimulated by DNA damage, as well 
as by forming complexes with other factors such 
as p14ARF and MDM2, which in turn regulate the 
G1-S phase cell cycle progression [8].
The causal link between certain types of human 
papillomavirsus (HPV) and anogenital cancer is well 
established. Some high risk HPVs (such as types 16, 
18, 31, 33, 35, 39 and 45) selectively infect epithelium 
of the cervix, vagina, vulva, penis and anus and are re-
lated with squamous cell carcinoma [9–11]. The most 
prevalent HPV in cervical cancers is type 16, account-
ing for about half of the cases in the Europe and United 
States [12]. Some studies have alluded to a role of HPV 
in the pathogenesis of OC although the frequency 
of HPV DNA in ovarian carcinomas is highly variable 
[13–15]. The significance of these findings has been 
controversial, since other studies failed to confirm the 
presence of HPV in ovarian tissues [16,17].
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Despite the number of reports indicating the pres-
ence of HPV in OC tissues there is no evidence linking 
HPV infection to clinicopathological and molecular 
features of OC. The function of HPV E6 oncoprotein 
in primary ovarian cancer cells with respect to cell 
cycle proteins expression in situ is not clear.
We designed this study to investigate the expres-
sion of key cell cycle proteins p53, p16INK4a, pRb , cyclin 
D1, the presence of HPV, clinicopathological features 
of OC, and the clinical follow up in a group of 53 ovar-
ian cancer patients.
MATERIALS AND METHODS
Patients and tumor samples. Formalin-fixed, 
paraffin-embedded tumor specimens were studied 
from 53 patients with primary serous ovarian cancer. 
All patients received the treatment at the department 
of Oncogynecology at the Kyiv National Cancer Institute, 
Ukraine. The mean age at diagnosis was 50.7±1.9 (range 
16–79) years. The study protocol was approved by the 
Ethical Committee permission of Institute of Experimental 
Pathology, Oncology and Radiobiology of NAS of Ukraine 
for studies with human materials.
Sections of 4-μm thickness were cut from the 
paraffin blocks for hematoxylin-eosin staining and 
a detailed histopathological classification was as-
signed according to the criteria of the WHO (1981). 
Clinical stages were determined according to the 
International Federation of Gynecology and Obstetrics 
system (FIGO) which specifies tumor size and the 
extent to which it has spread.
Immunohistochemistry. Immunohistochemical 
staining was performed using the primary mouse 
monoclonal antibodies against HPV16 E6+HPV18 E6, 
dilution 1:100 (clone C1P5, AbCam); p53 (clone DO7), 
pRb, dilution 1:50 (clone Rb1), cyclinD1, dilution 
1:50 (clone DCS-4) and p16INK4a, dilution 1:40 (clone 
E6H4, DakoCytomation). DO7 antibody reacts both 
with wild-type and mutant p53 protein, recognizing 
an epitope between amino acids 21 and 25 [18,19]. Im-
munopositivity was determined to be distinct nuclear 
staining for p53 and both nuclear and cytoplasmic 
immunostaining for p16INK4a, pRb and cyclin D1.
After routine deparaffinization in xylene and rehy-
dration through serial dilutions of alcohol the sections 
were subjected to heat-mediated antigen retrieval 
for 15 minutes in citrate buffer (pH 6.0). To minimize 
nonspecific binding, blocking was performed with 
1% BSA at RT for 30 minutes. The primary antibodies 
were applied overnight at 4 °C followed by Envision 
visualization mouse system (DakoCytomation). 3,3-di-
aminobenzidine (DAB) was used as the chromogen 
for 5 minutes and haematoxylin, as a counterstain. 
Stained sections were dehydrated and mounted 
in xylene.
The percentage of immunopositive cells was 
evaluated (labeling index — LI). In each sample 600–
700 cells were counted. Cervical intraepithelial neo-
plasia III (CIN III) known to be positive for HPV16 was 
used as a positive control for HPV 16/18 E6 protein 
staining. Negative controls were obtained by omitting 
the primary antibodies.
The immunoreactivity for all cell cycle regula-
tory proteins investigated in this study was evaluated 
as strong and weak according to the values of median 
(Me) of its expression (Table 1).
Table 1. Evaluation of the immunohistochemistry
Antigen Evaluation criteriaweak expression, Me, % strong expression, Me, %
p53 ≤30.0 >30.0
p16INK4a ≤32.0 >32.0
pRb ≤1.0 >1.0
cyclin D1 ≤49.0 >49.0
For E6 HPV 16 and 18 oncoprotein, staining was de-
fined to be negative (no stained cells), focal (10–30% 
of stained cells, spreading in one tissue area) and 
diffuse (30–100% of stained cells spreading in several 
areas in the tissue).
DNA extraction. Formalin-fixed, paraffin-embed-
ded samples cut into 20 μm slices, were deparaffinized 
in xylene and rehydrated in 96 and 70% ethanol. The 
samples were processed either with QIAamp DNA Mini 
kit (Qiagen) according to the instructions of manufac-
turer. DNA was eluted from the columns in a volume 
of 50 ul of AE buffer; or by phenol chloroform ex-
traction following Proteinase K (20 ug/ml) digestion 
in 475 ul of digestion buffer, (100mM Tris-HCl (pH 8.5), 
10% SDS) at 55 °C. DNA was precipitated with ethanol 
and dissolved in AE buffer.
PCR amplification. The quality of DNA from each 
tumor specimens was confirmed by PCR using prim-
ers for b-globin (224 bp): β-globin F: CACTCAGTGTG-
GCAAAGGTGCCC; β -globin R: GGCACTGACTCTCTCT-
GCCT.
The HPV type-specific primers sets were used for 
amplification of E6 gene fragment of HPV types 16 and 
18: HPV 16 F: 5'-TTAGAATGTGTGTACTGCAAGC-3'; 
HPV 16 R: 5'-TTGTCCAGATGTCTTTGCTT-3'; HPV 
18 F: 5'-CACTTCACTGCAAGACATAG-3'; HPV 18 R: 
5'-CTATGTTGTGAAATCGTCGT-3’.
PCR reactions were performed in a total volume 
of 50 ul. The reaction mixture contained 1x GoTaq PCR 
buffer (Promega, USA), 3 mM MgCl2, 0.2 mM each dNTP, 
2.0 μM primers and 1.25 u Taq polymerase (Promega, 
USA) and 300 ng of DNA. Samples were amplified on ABS 
programmable thermocycler (Applied Biosystems). The 
amplification was carried out at 92 °C for 5 min followed 
by 37 cycles: denaturation at 92 °C for 30 s, annealing 
at 53 °C for 30 s and extension at 72 °C for 1 min. The 
final extension was for 10 min at 72 °C.
The amplified E6 gene fragments were of 281 bp for 
HPV16, 326 bp for HPV18 and were visualized on 2 per-
cent agarose gels. As positive control for HPV types 
16 and 18 amplification, HeLa and CasKi cell lines DNA 
were used, and water as template was used as a nega-
tive control.
Statistical analysis. The association between 
clinicopathological characteristics of patients and bio-
molecular markers expression was assessed by the 
Kruskal — Wallis test for two or more groups. The non-
parametric Fisher exact-test was used to compare the 
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biomolecular markers expression rank between different 
groups. A p-value of ≤0.05 was considered to be statisti-
cally significant. The survival analyses were estimated 
by the Kaplan — Meier method. Survival was calculated 
from the date of diagnosis until patient’s death or until 
the last date the patient was known to be alive (range 
from 12 to 84 months). The statistical significance of dif-
ferences between survival times was determined by the 
log-rank test in univariate analysis. Statistical analysis 
was carried out using the Statistica 7 program.
RESULTS
Immunohistochemical analysis. The distribution 
of patients with respect to FIGO system staging and 
tumor differentiation were as follows: 14 (26.5%) pa-
tients were stage I/II and 39 (73.5%) patients — stage 
III/IV; 5 (9.4%) patients had well differentiated tumors 
(G1), 22 (41.5%) patients — moderately differentiated 
tumors (G2) and 26 (49.1%) — poorly differentiated 
(G3) tumors (Table 2). The median age was 51 years.
Table 2. Distribution of ovarian cancer patients according to the clinico-
pathological parameters
Clinicopathologic parameters Number of patients (%)
Age ≤51
>51
28 (52.8)
25 (47.2)
FIGO I
II
III
IV
1 (2.0)
13 (24.5)
29 (54.7)
10 (18.8)
Total 53 (100.0)
Tumor differentiation G1
G2
G3
5 (9.4)
22 (41.5)
26 (49.1)
Immunohistochemical expression of p53, p16INK4a, 
pRb and cyclin D1 was examined in OC tissues with 
some exceptions (Table 3). The immunopositivity 
of p53 was revealed in 86.8%, p16INK4a in 92.5%, pRb 
in 51.0% and cyclin D1 in 83.3% of ovarian carcinomas 
(see Table 3). Figure 1 shows representative examples 
of strong p53 (Fig. 1, a), p16INK4a (Fig.1b), Cyclin D1 (Fig. 
1, c) and pRb (Fig. 1, d) staining in ovarian carcinomas.
Table 3. Immunohistochemical analysis of cell cycle regulatory proteins 
in serous ovarian cancer
Protein
Number 
of positive 
samples (%)
Strong ex-
pression, 
n (%)
Weak ex-
pression, 
n (%)
Mean values, LI, 
% (variation)
p53 (n = 53)
p16INK4a (n = 53)
pRb (n = 52)
CyclinD1(n = 49)
46 (86.8)
49 (92.5)
27 (51.0)
40 (83.3)
26 (49.1)
24 (45.3)
24 (45.4)
22 (45.8)
20 (37.7)
25 (47.2)
3 (5.6)
18 (37.5)
31.5±2.9 (4–73)
32.5±2.9 (6–94.8)
13.5±2.7 (1–88)
46.8±4.7 (8–97)
Based on LI, the mean level of expression of the 
cell cycle proteins in OCs were as follow: p53 — 
31.5±2.9%; p16INK4a — 32.5±2.9%; pRb- 13.5±2.7%; 
Cyclin D1 — 46.8±4.7%.
An increasing trend between increasing median 
values of p53 and pRb and decreasing tumor differen-
tiation was observed (Kruskal — Wallis test) (Table 4). 
Significantly higher median cyclin D1 value was ob-
served in well and moderately differentiated carcinomas 
(Grade 1 and 2) compared with poorly differentiated 
tumors (Grade 3) (p=0.05). Median p16INK4a value was 
significantly higher (39.0 vs 21.0) in poorly differenti-
ated tumors as compared to the moderately or highly 
differentiated tumors (p=0.05). A significant correlation 
between median values of the p53, pRb, p16INK4a, and 
cyclin D1expression, the median of patients’ age, and 
FIGO staging could not be confirmed to p≤0.05.
We used Fisher’s exact test to analyze the relation 
between clinicopathologic parameters and patterns 
a
b
c
d
Fig. 1. Immunohistochemistry on primary ovarian carcinomas. 
a — strong p53 expression in a poorly differentiated (G3) serous 
OC. b, c, d — strong expression of p16INK4a, Cyclin D1 and pRb 
proteins in moderately differentiated (G2) serous OC. Magnifi-
cation x400
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of cell cycle protein p53, p16INK4a, pRb and cyclin D1 ex-
pression in OC (Table 5). We determined the pattern 
of p53, p16INK4a, and cyclin D1 expression to be de-
pendent on tumor differentiation. Poorly differentiated 
(Grade 3) tumors had higher percentage of strong 
p53 and p16INK4a staining (approximately 61.0% each), 
whereas well and moderately differentiated (Grade 
1/2) tumors displayed lower p53 and p16INK4a staining 
(44.5% and 29.6%, p=0.02, and p  .0000 respectively). 
Conversely, the percentage of strong cyclin D1 expres-
sion increased with degree of differentiation of ovarian 
carcinomas (66.6%) compared to poor differentiation 
(26.9%) (p=0.0000). However, pRb immunoreactivity 
in OC between well/moderately and poorly differenti-
ated samples (p=0.47) did not change significantly 
in this test (Table 5).
Table 4. The median of expression of cell cycle regulatory proteins 
in ovarian carcinomas according to the tumor differentiation
Tumor differen-
tiation
Median values, %
p53 p16INK4a pRb Cyclin D1
G1 30.5 21.0 0 79.4
G2 29.5 25.0 4.0 54.5
G3 35.6 39.0 1.0 29.2
Kruskal-Wallis test 0.4 0.05 0.2 0.05
Table 5. Percentage of cases showing different pattern of immunohisto-
chemical positivity for p53, p16INK4a, pRb and cyclin D1 according to the 
clinico-pathological parametrs
Covariate n
The number of patients with different pattern of expres-
sion, %
p53 p16INK4a pRb CyclinD1
neg/
weak strong
neg/
weak strong
neg/
weak strong
neg/
weak strong
FIGO
I/II
III
IV
Fisher ex-
act test
14
29
10
64.3*
44.8*
50.0
35.7*
55.2*
50.0
57.2*
55.2
50.0*
42.8*
44.8
50.0*
71.4*
55.2*
30.0
28.5*
44.8*
70.0
42.8*
41.4
60.0*
57.2*
58.6
40.0*
*p = 0.006 *p = 0.4 *p = 0.02 *p = 0.02
Grade
1/2
3
27
26
55.5
38.5
44.5
61.5
70.3
38.5
29.6
61.5
55.5
50.0
44.4
50.0
33.3
73.1
66.6
26.9
Fisher ex-
act test
p = 0.02 p = 0.0000 p = 0.47 p = 0.0000
*Significant differences between groups.
A strong p53 and pRb expression was observed 
in advanced disease (FIGO stage III) and strong cyclin 
D1 expression was higher in patients with early stage 
(FIGO stage I/II) of the disease (see Table 5).
Table 6. p53 and pRb expression according to E6 HPV oncoprotein local-
ization in ovarian cancer tissues
Protein ex-
pression, LI, 
% (variability)
HPV 16/18 E6 oncoprotein expression in ovarian cancer tissues
focal
n=2
diffuse
n=7
total HPV-positive
n=9
HPV negative
n=44
p53 39.0, 53.0 12.1±1.2 
(0–26.0)
19.6±4.08 
(0–53.0)
33.1±3.3 
(0–73.0)
pRb 19.0, 30.0 6.7±4.0 
(0–17.4)
10.7±2.2 
(0–30.0)
14.3±3.1 
(0–88.0)
Survival analysis. Clinical follow-up data were avail-
able for 42 patients with a median follow-up of 24 months 
(range 12–84 months) after the date of diagnosis. 
Survival curves were evaluated according to the immu-
nohistochemical expression levels of cell cycle proteins.
Ten OC patients died within 36 months after diagnosis 
(23.8%). The univariate analysis determined that a strong 
p53 and p16INK4a expression is associated with poor prog-
nosis of ovarian cancer (log-rank test p=0.02 and 0.05, 
respectively) (Fig. 2 and 3). In patients with highly and 
moderately differentiated tumors, a strong expression 
of cyclin D1 was correlated with reduced overall survival 
(log-rank test p = 0.04) (data not shown).
HPV status. We detected the presence of HPV DNA 
in 9 serous ovarian carcinomas (17.0%) by subtype spe-
cific PCR. Four patients had HPV type 16 (Fig. 4) and five 
patients had HPV type 18. The tissues from these same 
patients reacted positively to HPV 16/18 E6 antibody (Fig. 
5). Diffuse staining was observed in 7 and focal staining 
in 2 ovarian carcinomas, respectively.
We could detect a positive correlation between sig-
nificantly low levels of p53 expression in HPV positive 
OC tissues (19.6±4.08%) as compared to HPV- nega-
tive ovarian tumors (33.4±3.2%) (p=0.04) in our limited 
sample size. Interestingly, where HPV E6 oncoprotein 
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Fig. 2. Overall survival of ovarian cancer patients in relation 
to p53 immunopositivity showing that p53 strong expression 
was significantly correlated with poor prognosis as assesses 
by Kaplan — Meier analysis
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Fig. 3. Overall Kaplan — Meier survival curves of ovarian cancer 
patients show that p16INK4a strong expression correlated with 
poor prognosis
300 bp HPV16
β-globin
MW pos neg 1 2 3 4 5 6 7 8 9
200 bp
Fig. 4. HPV 16 E6 ORF specific PCR on DNA isolated from ar-
chived ovarian cancer tissues. The molecular marker is shown 
on the right. Negative and positive samples are indicated on the 
top of gel. b-globin as an internal control was used. Lines 
1,3,6,8 show HPV 16 positive ovarian cancer samples
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localization was focal, a high level of p53 expression 
(53.0 and 39.0%) was observed. In contrast, the tu-
mors with diffuse E6 oncoprotein localiazation had low 
p53 expression (8–26.0%) (Fig. 5, d, e). In two of the 
HPV- positive samples with diffuse E6 staining we did 
not see any p53 immunopositivity (Table 6) (Fig. 5, 
b, c). There was no significant difference between 
the presence of HPV in the tumors and p16INK4a, pRb 
and cyclin D1 expression level (p<0.05). However 
a trend for negative (4 samples) or lower pRb ex-
pression (4.0–26.0%) where tumors had diffuse HPV 
E6 staining, compared to tumors with focal E6 stain-
ing (19.0 and 30.0%) (see Table 6) was observed. 
We could not confirm a significant association between 
the histological grade, FIGO stage, patients’ age and 
the presence of HPV in ovarian cancer tissue (p<0.05).
DISCUSSION
One of the most important issues still unresolved 
in the treatment and management of OC is our inability 
to determine earliest changes that lead to the disease 
and target it for treatment. Researchers and physicians 
have not been able to develop targeted, optimized, 
risk-adjusted strategies for its treatment and then pre-
vention of recurrent OC. Thus, the identification of reli-
able biomarkers which can be used to generate targets 
for OC treatment represents an urgent necessity not 
only for translational researcher but also for clinical 
oncologists. We tried to address this issue by study-
ing an expression of cell cycle regulatory proteins and 
E6 HPV16/18 in a panel of 53 OC samples collected 
in our Institute and linked to clinical outcome data.
The cell cycle is controlled by a series of check-
points that guide the cell’s transition through its cycle 
[20]. Each of those checkpoints represents an or-
derly interaction between cyclins, cyclin-dependent 
kinases, and their inhibitors. Disruption of any of these 
components of cell cycle progression can cause a de-
regulation of normal cell cycle progression. This dys-
a b
c d
e
Fig. 5. Immunohistochemical detection of HPV 16/18 E6 oncop-
rotein in ovarian cancer tissues. a — positive control from cervi-
cal neoplasia (CIN III). In addition to the epithelium, endothelial 
cells of the blood vessels show E6 immunopositivity; b — HPV 
E6 oncoprotein diffuse immunopositivity in glandular structures 
of well differentiated ovarian cancer and absence of oncoprotein 
in stroma. c — the same tissue used for E6 staining in panel 
b showing p53 negative expression; d — E6 oncoprotein diffuse 
immunopositivity in moderately differentiated ovarian carcinoma; 
e — p53 weak expression in the same ovarian carcinoma tissue 
used for E6 staining in panel d. Magnification x400
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regulation may be sufficient for malignancy to develop 
and with additional mutations or other environmental 
triggers, progress. Several studies point to the cell 
cycle regulatory proteins including Cyclin D as possible 
useful markers in various cancers [21–23]. In this ret-
rospective study, the expression of cell cycle proteins 
p53, p16INK4a, pRb and cyclin D1 in a series of 53 ovar-
ian serous carcinomas and the status of HPV was 
examined. The immunohistochemical results were 
analyzed and correlated with the clinicopathological 
data. In our series of experiments, we observe strong 
p53, p16INK4a, pRb and cyclin D1 expression in about 
50% of OC tissues examined with a significant cor-
relation between p53, p16INK4a and cyclin D1 status, 
histological grade and clinical stage of OC.
Although limited by samples size, our results in-
dicate that high expression of Cyclin D1, p16INK4a and 
p53 correlate with poor prognosis. In particular, our 
analysis demonstrated that localization and increased 
expression of these key cell cycle G1/S phase transi-
tion regulators is linked to more aggressive disease and 
a lower expression can be correlated with longer surviv-
als. We were able to show that high Cyclin D1 expression 
was a significant indicator for poor prognosis in patients 
with early stages of disease or well differentiated tu-
mors (see Table 5). These results are consistent with 
several studies indicating that cyclin D1 overexpression 
is an early event in ovarian carcinogenesis [7].
The literature evaluating and implicating p16INK4a 
as both a diagnostic and prognostic marker in OC is ac-
cumulating. p16INK4a is a cyclin-dependent kinase IV in-
hibitor and is expressed in a limited range of normal 
tissues and tumors [24]. Therefore its dysregulation 
in various tissues is thought to be associated with 
malignant changes. The normal function of p16INK4a 
is negative regulation of cell cycle. It has also been 
reported to be expressed in tissues that are devel-
opmentally regulated to senesce [24]. Interestingly, 
we observe an overexpression of p16INK4a in the late 
stages of OC. Our immunohistochemical screen 
revealed that p16INK4a is either weakly or strongly 
upregulated in 92.5% OC tissues studied. The prog-
nosis for patients with strong p16INK4a expression was 
poorer than those with weak expression of p16INK4a 
[25, 26]. The normal localization of p16INK4a has been 
reported to be nuclear [24]. We observed mostly 
nuclear-cytoplasmic p16INK4a staining in ovarian cancer 
cells. One of the reasons for this observation might 
be either due to very high nuclear localization of this 
protein leading to a leakage during tissue preservation 
process, or an aberrant overexpression of p16INK4a. 
Since our analysis determined a significantly positive 
correlation between high p16INK4a expression, late 
stage disease and poor outcome for patients, we posit 
that this might represent either a mutant form of the 
protein or an as yet uncharacterized function of the 
native protein.
Disruptions of the p16-CDK4/CyclinD1 pathway 
(pRb pathway) and the p14ARF-MDM2-p53 pathway 
(p53 pathway) are important mechanisms in the devel-
opment of malignant tumors including ovarian malig-
nancies [27]. Each member of p53- and pRb-pathways 
has regulatory roles in initiation and progression of tu-
mor growth [28]. We confirm this finding with our own 
data where p53 was present but at a lower intensity 
in high grade (1/2) tumors and was highly expressed 
in poorly differentiated tumors. These results indicated 
that p53 plays a critical role in later stages where the 
disease is progressing.
The high risk HPVs are critical etiologic risk factors 
for development of malignancies in the lower female 
genital tract [9]. The significance of high risk HPVs 
in upper genital tract, including ovarian cancer is con-
troversial. A literature review shows highly variable 
reported frequency of HPV infection in ovarian carcino-
mas from 4.2 to 37.5%, while many other reports failed 
to confirm HPV DNA in ovarian neoplasms [13–17, 29]. 
In this study PCR analysis demonstrated HPV DNA 
in 17.0% (9 from 53) ovarian serous carcinomas. All 
the HPV 16 and 18 DNA positive OC tissues showed 
immunopositivity for E6 oncoprotein. In ovarian cancer 
samples, HPV E6 staining was adjacent to peritumoral 
area and was detected in glandular structures of ovar-
ian carcinomas and was absent in stroma. The protein 
products of high risk HPV E6 and E7 oncogenes disturb 
the function of key cell cycle regulators p53 and pRb 
as has been elegantly demonstrated in cervical cancer 
model [30].The HPV E6 gene product interacts with 
wild type cellular p53 protein and subverts its func-
tion [30]. Oncoprotein E7 forms a complex with pRb 
leading to its functional inactivation through proteolytic 
degradation in cervical cancer model [30]. Interest-
ingly, in our small subset of nine samples that tested 
positive for diffused HPV E6 staining, we observed 
an acute downmodulation of p53 expression. Since 
our p53 antibody (clone DO7) recognized both the wild 
type and the mutant form of p53 [18, 19] we reason 
that detection of p53 in HPV positive tissues might rep-
resent the presence of mutant p53. The p16INK4a, pRb 
and cyclin D1 expression levels were not significantly 
different in HPV-positive and negative ovarian cancer 
tissues. A strong expression of p16INK4a has been re-
ported in HPV positive cervical cancer [31, 32]. The 
proposed mechanism postulates that the upregulation 
of p16INK4a in cervical cancer is due to the modulation 
of pRb by the viral E7 gene product [30]. The high ex-
pression of p16INK4a in HPV- positive tumors in our study 
might still result from HPV E7 modulation, however, 
a larger sample set needs to be analyzed to determine 
the correlation with a statistical significance.
In conclusion, we demonstrate that a major-
ity of moderately and poorly differentiated ovarian 
carcinomas are characterized by strong expression 
of p53 and p16INK4a proteins, while strong staining with 
cyclin D1 antibody was observed in well differentiated 
tumors. This indicates that an aberrant expression 
of cyclin D1 might be an early event in the OC devel-
opment. We show that, patients with high positivity for 
p53, p16INK4a and Cyclin D1 had a poor prognosis and 
reduced overall survival. The presence of high risk 
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HPV 16 and 18, although controversial, was detected 
in a small subset of nine samples with significantly low 
p53 expression profile.
These findings, although in need of confirmation 
on a larger pool of cases, indicate that p53, p16INK4a 
and Cyclin D1 expression and HPV may represent 
a promising tool toward the identification of patients 
with poorer prognosis who may benefit from more ag-
gressive therapy and HPV screening.
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